Physiopathologie, diagnostic et prise en charge des métastases osseuses du cancer de prostate

25 novembre 2008

Auteurs : T. Lebret, A. Méjean
Référence : Prog Urol, 2008, 18, S349, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 2001 ;  27 : 165-176 [cross-ref]
 
Eaton C.L., Coleman R.E. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment Cancer Treat Rev 2003 ;  29 : 189-198 [cross-ref]
 
Mundy G.R. Mechanisms of bone metastasis Cancer 1997 ;  80 : 1546-1556 [cross-ref]
 
Scalliet P. Carcinoma of the prostate: treatment of bone metastasis Acta Urol Belg 1996 ;  64 : 87-90
 
Diamond T.H., Higano C.S., Smith M.R., Guise T.A., Singer F.R. Osteoporosis in men with prostate carcinoma receiving androgendeprivation therapy: recommendations for diagnosis and therapies Cancer 2004 ;  100 : 892-899 [cross-ref]
 
Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer Arch Intern Med 2006 ;  166 : 465-471 [cross-ref]
 
Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 2005 ;  352 : 154-164 [cross-ref]
 
Clarke N.W., McClure J., George N.J. The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer Scand J Urol Nephrol 1993 ;  27 : 475-483 [cross-ref]
 
Maillefert J.F., Sibilia J., Michel F., Saussine C., Javier R.M., Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma J Urol 1999 ;  161 : 1219-1222 [cross-ref]
 
Major P.P., Lipton A., Berenson J., Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases Cancer 2000 ;  88 : 6-14 [cross-ref]
 
Smith M.R., Boyce S.P., Moyneur E., Duh M.S., Raut M.K., Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer J Urol 2006 ;  175 : 136-139 [cross-ref]
 
Weinfurt K.P., Li Y., Castel L.D., et al. The significance of skeletal- related events for the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 2005 ;  16 : 579-584 [cross-ref]
 
Ellis W.J., Pfitzenmaier J., Colli J., Arfman E., Lange P.H., Vessella R.L. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow Urology 2003 ;  61 : 277-281 [inter-ref]
 
Melchior S.W., Corey E., Ellis W.J., et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate Clin Cancer Res 1997 ;  3 : 249-256
 
Edlund M., Sung S., Chung L. Modulation of prostate cancer metastasis to bone J Cell Biochemistry 2004 ;  91 : 706-717
 
Mundy G.R. Mechanisms of bone metastasis Cancer suppl 1997 ;  80 : 1546-1556 [cross-ref]
 
Nelson J., Bagnato A., Battistini B., et al. The endothelin axis:emerging role in cancer Nat Rev Cancer 2003 ;  2 : 584-593
 
Takuwa Y., Masaki T., Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae Biochem Biophys Res Commun 1990 ;  170 : 998-1005 [cross-ref]
 
Cramer S.D., Chen Z., Peehl D.M. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP stimulated cAMP accumulation in mouse osteoblast J Urol 1996 ;  156 : 526-531 [cross-ref]
 
Yeung F., Law W.K., Yeh C.H., et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells J Biol Chem 2002 ;  277 : 2468-2476 [cross-ref]
 
Lenchik L., Kiebzak G.M., Blunt B.A. International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee What is the role of serial bone mineral density measurements in patient management? J Clin Densitom 2002 ;  5 : S29-38
 
Cree M., Soskolne C.L., Belseck E., Hornig J., McElhaney J.E., Brant R., et al. Mortality and institutionalization following hip fracture J Am Geriatr Soc 2000 ;  48 : 283-288 [cross-ref]
 
Cummings S.R., Black D.M., Nevitt M.C., et al. Bone density at various sites for prediction of hip fractures The Study of Osteoporotic Fractures Research Group Lancet 1993 ;  341 : 72-75 [cross-ref]
 
Melton L.J., Atkinson E.J., O’Connor M.K., O’Fallon W.M., Riggs B.L. Bone density and fracture risk in men J Bone Miner Res 1998 ;  13 : 1915-1923 [cross-ref]
 
Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ 1996 ;  312 : 1254-1259 [cross-ref]
 
Demers L.M., Costa L., Lipton A. Biochemical markers and skeletal metastases Cancer 2000 ;  88 : 2919-2926 [cross-ref]
 
Lipton A., Costa L., Ali S.M., Demers L.M. Bone markers in the management of metastatic bone disease Cancer Treat Rev 2001 ;  27 : 181-185 [cross-ref]
 
Saad F., Gleason D.M., Murray R., et al. Zoledronic Acid Prostate Cancer Study Group Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 2004 ;  96 : 879-882 [cross-ref]
 
Lein M., Wirth M., Miller K., et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression Eur Urol 2007 ;  52 : 1381-1387 [cross-ref]
 
Koizumi M., Yonese J., Fukui I., Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone BJU Int 2001 ;  87 : 348-351 [cross-ref]
 
Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E., Delmas P.D. Markers of bone turnover for the management of patients with bone metastases from prostate cancer Br J Cancer 2000 ;  82 : 858-864 [cross-ref]
 
Koizumi M., Yonese J., Fukui I., Ogata E. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer J Urol 2002 ;  167 : 1863-1866 [cross-ref]
 
Vinholes J., Coleman R., Lacombe D., et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion European Organization for Research and Treatment of Cancer Br J Cancer 1999 ;  80 : 221-228 [cross-ref]
 
Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Cancer 2008 ;  113 : 193-201 [cross-ref]
 
Costa L., Demers L.M., Gouveia-Oliveira A., et al. Prospective evaluation of the peptide-bound collagen type I cross-links Ntelopeptide and C telopeptide in predicting bone metastases status J Clin Oncol 2002 ;  20 : 850-856 [cross-ref]
 
Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 2005 ;  97 : 59-69 [inter-ref]
 
Houzé P., Bellik B., Extra J.M., Bouro F., Bousquet Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer B Clin Chim Acta 1999 ;  281 : 77-88
 
Wilt T.J., Ensrud K.E. The if’s, and’s, or but’s regarding bisphosphonates for prostate cancer J Natl Cancer Inst 2007 ;  99 : 744-745 [cross-ref]
 
Fournier G., Valéri A. Treatment of metastatic prostate cancer: certainty and doubts Presse Med 1998 ;  27 : 1996-2002
 
Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2002 ;  2 : 584-593 [cross-ref]
 
Clezardin P., Teti A. Bone metastasis: pathogenesis and therapeutic implications Clin Exp Metastasis 2007 ;  24 : 599-608 [cross-ref]
 
Delmas P.D. Bisphosphonates in the treatment of bone diseases N Engl J Med 1996 ;  335 : 1836-1837 [cross-ref]
 
Lee M.V., Fong E.M., Singer F.R., Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells Cancer Res 2001 ;  61 : 2602-2608
 
Stearns M.E., Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice Clin Exp Metastasis 1998 ;  16 : 693-702 [cross-ref]
 
Clézardin P., Gligorov J., Delmas P. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis Joint Bone Spine 2000 ;  67 : 22-29
 
Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 2002 ;  62 : 6538-6544
 
Colombel M. The role of bisphosphonates in the treatment of bone metastases from urogenital cancer Prog Urol 2003 ;  13 : 18-23
 
Major P.P., Lipton A., Berenson J., Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases Cancer 2000 ;  88 : 6-14 [cross-ref]
 
Cramer J.A., Amonkar M.M., Hebborn A., Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 2005 ;  21 : 1453-1460 [cross-ref]
 
Saad F., Gleason D.M., Murray R., et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma J Natl Cancer Inst 2002 ;  94 : 1458-1468 [cross-ref]
 
Green J.R. Preclinical pharmacology of zoledronic acide Semin Oncol 2002 ;  29 : 3-11 [cross-ref]
 
Dearnaley D.P., Sydes M.R., Mason M.D., et al. A double-blind, placebo- controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial) J Natl Cancer Inst 2003 ;  95 : 1300-1311 [cross-ref]
 
Ernst D.S., Tannock I.F., Winquist E.W., et al. Randomized, doubleblind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain J Clin Oncol 2003 ;  21 : 3335-3342 [cross-ref]
 
Small E.J., Smith M.R., Seaman J.J., Petrone S., Kowalski M.O. Combined analysis of two multicenter, randomized, placebocontrolled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer J Clin Oncol 2003 ;  21 : 4277-4284 [cross-ref]
 
Saad F., Perrotte P., Bénard F., McCormack M., Karakiewicz P.I. Bone health in men with prostate cancer: diagnostic and therapeutic considerations Can J Urol 2005 ;  12 : 9-15
 
Carducci M.A., Padley R.J., Breul J., et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial J Clin Oncol 2003 ;  21 : 679-689 [cross-ref]
 
Gaze M.N., Kelly C.G., Kerr G.R., et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules Radiother Oncol 1997 ;  45 : 109-116 [cross-ref]
 
Steenland E., Leer J.W., van Houwelingen H., et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study Radiother Oncol 1999 ;  52 : 101-109 [cross-ref]
 
Rose C.M., Kagan A.R. The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology Int J Radiat Oncol Biol Phys 1998 ;  40 : 1117-1124 [cross-ref]
 
Di Lorenzo G., Autorino R., Ciardiello F., et al. External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life Oncol Rep 2003 ;  10 : 399-404
 
Ben-Josef E., Shamsa F., Youssef E., Porter A.T. External beam radiotherapy for painful osseous metastases: pooled data dose response analysis Int J Radiat Oncol Biol Phys 1999 ;  45 : 715-719 [cross-ref]
 
Hartsell W.F., Scott C.B., Bruner D.W., et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases J Natl Cancer Inst 2005 ;  97 : 798-804 [cross-ref]
 
Gaze M.N., Kelly C.G., Kerr G.R., et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules Radiother Oncol 1997 ;  45 : 109-116 [cross-ref]
 
Kraeber-Bodéré F., Campion L., Rousseau C., Bourdin S., Chatal J.F., Resche I. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement Eur J Nucl Med 2000 ;  27 : 1487-1493
 
Robinson R.G., Preston D.F., Schiefelbein M., Baxter K.G. Strontium 89 therapy for the alliation of pain due to osseous metastases JAMA 1995 ;  274 : 420-424 [cross-ref]
 
Quilty P.M., Kirk D., Bolger J.J., et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer Radiother Oncol 1994 ;  31 : 33-40 [cross-ref]
 
Bolger J.J., Dearnaley D.P., Kirk D., et al. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial UK Metastron Investigators Group Semin Oncol 1993 ;  20 : 32-33
 
Lee C.K., Aeppli D.M., Unger J., Boudreau R.J., Levitt S.H. Strontium- 89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience Am J Clin Oncol 1996 ;  19 : 102-107 [cross-ref]
 
Crook J. Radiation therapy and radio-nuclides for palliation of bone pain Urol Clin N Am 2006 ;  33 : 219-226 [inter-ref]
 
Oosterhof G.O., Roberts J.T., de Reijke T.M., et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer Genitourinary Group Eur Urol 2003 ;  44 : 519-526 [cross-ref]
 
Lee C.K., Aeppli D.M., Unger J., Boudreau R.J., Levitt S.H. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience Am J Clin Oncol 1996 ;  19 : 102-107 [cross-ref]
 
Lewington V.J., McEwan A.J., Ackery D.M., et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone Eur J Cancer 1991 ;  27 : 954-958 [cross-ref]
 
Porter A.T., McEwan A.J. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomised controlled trial Semin Oncol 1993 ;  20 : 38-43
 
Quilty P.M., Kirk D., Bolger J.J., et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer Radiother Oncol 1994 ;  31 : 33-40 [cross-ref]
 
Brundage M.D., Crook J.M., Lukka H. Use of strontium-89 in endocrine- refractory prostate cancer metastatic to bone Provincial Genitourinary Cancer Disease Site Group Cancer Prev Control 1998 ;  2 : 79-87
 
Schwarz E.M., Ritchlin C.T. Clinical development of anti-Rankl therapy Arthritis Research & Therapy 2007 ;  9 : 1-6
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.